focus -WSS

focus

author：hotspot 2025-09-28 02:26:49 - browse：9

John Thune raises one hand while speaking to the press at the Capitol 2024 — politics coverage from STAT — Sen. John Thune is one of a group of lawmakers that is working on 340B reform legislation. BRENDAN SMIALOWSKI/AFP via Getty Images

WASHINGTON — A bipartisan group of senators released a draft of legislation to resolve controversial disputes in the 340B drug discount program, according to documents obtained by STAT.

The drug discount program, which was designed to support providers that serve low-income patients, has been increasingly contentious as it’s grown in recent years. The draft legislation makes a number of changes to address some of the most controversial points, including its rules over so-called “contract pharmacies” and which subsidiaries can qualify for discounts.

The draft would also require more oversight, and it would give the Health Resources and Services Administration more money to do it with a new user fee program. Providers would pay HRSA up to 0.1% of the savings it receives from the program.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： The nurse manager staffing crisis is hurting patients

leisure time

WSS

Covid isolation guidance eased by the CDC

ALS groups 'won't be played again' by the FDA, drug sponsors

A Q&A with Aletha Maybank, AMA’s chief health equity officer

How I ended up pumping milk in a bathroom stall at JPM 2024

Three issues to watch in global health in 2024

Fauci’s Covid grilling leads GOP to weigh foreign research rules

knowledge

focus

focus

The cancer drug shortage isn’t new — and neither are the solutions

Biotech reporter’s notebook: A sunnier mood at JPM 2024

What does generative AI mean for health care? We asked experts

New menopause drug shows promise in relief for hot flashes

DIEP, the 'gold standard' of breast reconstruction, is under threat

Clinical trials giant ICON acquires HumanFirst

Jerome Adams on the need for new antivirals for Covid

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

In Memoriam: Notable people who died in 2023

As JPM 2024 winds down, some health tech firms project optimism

Wikipedia

Pfizer highlights cancer drugs it thinks could reignite investor interest

Congress gives doctors Medicare pay bump

Risky weight loss products often used by teens globally, per study

AstraZeneca loses challenge to Medicare drug price negotiation

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Readout LOUD podcast: live from JPM 2024

knowledge

leisure time

leisure time

focus